Skip Navigation

News & Resources


Subscribe to NHLBI Press Releases
August 17, 2016

Study Shows Acetaminophen Can Be Tolerated by Young Children With Mild, Persistent Asthma

WHAT: In a study of children with mild, persistent asthma, scientists found that acetaminophen was tolerated without the worsening of asthma, when compared with ibuprofen use. The study, funded by the National Heart, Lung, and Blood Institute’s asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.

Subscribe to NHLBI In The News
August 18, 2016 : Journal of Clinical Pathways

The anticancer drug ibrutinib does not appear to inhibit response to the flu vaccine in patients with chronic lymphocytic leukemia (CLL), despite an impaired immune system, according to a new study. Researchers gave influenza vaccine to a small group of CLL patients participating in a clinical trial of ibrutinib. More than one-quarter of the patients showed evidence of a positive response to the flu vaccine three months after receiving it. The findings lend support to routine immunization against the flu in patients with CLL, the researchers said. The study, published in JAMA Oncology, was funded by NHLBI.

August 18, 2016 : GenomeWeb

Researchers are reporting identification of a large number of genes that they have linked to an increased risk of developing cardiovascular disease, including heart attack and stroke.  The researchers analyzed gene-expression data from tissue samples taken from hundreds of patients with coronary artery disease.  They identified more than 1,000 genes that appear to be associated with an increased risk for heart disease, the nation’s leading cause of death. The study, published in Science, was partly funded by NHLBI.

September 9, 2016
6701 Rockledge Drive, (Conference Room 9100/9104) Bethesda, MD 20892
The severe anemia associated with hematologic disorders such as β thalassemia, myelodysplastic syndrome, and congenital dyserythropoietic anemia, arises from defects in late stage erythroid maturation (dyserythropoiesis). In contrast to anemias resulting from early stage defects, this group of disorders are resistant to erythropoietin (EPO) therapy since late-stage erythroblast differentiation and maturation is EPO independent. Transfusion, often associated with iron overload and alloimmunization, remains the principal approach to care. Fortunately, however, several molecular determinants of dyserythropoiesis have been recently identified. It is possible that these discoveries may reveal common pathways leading to dyserythropoiesis. This workshop will consider the gaps in our knowledge and technology that are barriers to our understanding of the underlying biologies that may lead to effective new treatments for late stage erythroid maturation defects. This workshop will also provide an opportunity for the research community to cooperatively consider the essential next steps for the field.
September 26, 2016 to September 27, 2016
This workshop has two main objectives: (a) to assess recent developments in statistical methods relevant to NHLBI studies; (b) to identify the major challenges and important issues related to these statistical and analytical methods.